✦ LIBER ✦
Point-of-care testing shows clinically relevant variation in the degree of inhibition of platelets by standard-dose abciximab therapy during percutaneous coronary intervention
✍ Scribed by Michael J. Ray; Darren L. Walters; Nicholas Bett; James Cameron; Peter Wood; Con Aroney
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 93 KB
- Volume
- 62
- Category
- Article
- ISSN
- 1522-1946
No coin nor oath required. For personal study only.